MRI-guided focal laser ablation of prostate cancer: a prospective single-arm, single-center trial with 3 years of follow-up
George, Arvin K
Hoang, Anthony N
Rastinehad, Ardeshir R
Lebastchi, Amir H
Siddiqui, Mohummad Minhaj
Merino, Maria J
Choyke, Peter L
Shih, Joanna H
Wood, Bradford J
Pinto, Peter A
JournalDiagnostic and interventional radiology (Ankara, Turkey)
PublisherAVES Ibrahim Kara
MetadataShow full item record
AbstractPURPOSE: We aimed to assess post-interventional and 36-month follow-up results of a single-center, single-arm, in-bore phase I trial of focal laser ablation (FLA) guided by multiparametric magnetic resonance imaging (mpMRI). METHODS: FLA procedures were done in-bore MRI using a transperineal approach. Primary endpoints were feasibility and safety expressed as lack of grade 3 complications. Secondary endpoints were changes in international prostate symptom score (IPSS), sexual health inventory for men (SHIM), quality of life (QoL) scores, and serum prostate specific antigen (PSA) levels. Treatment outcomes were assessed by combined mpMRI-ultrasound fusion-guided and extended sextant systematic biopsy after 12, 24, and optionally after 36 months. RESULTS: Fifteen participants were included. Seven patients (46.67%) had Gleason 3+3 and 8 patients (53.33%) had Gleason 3+4 cancer. All patients tolerated the procedure well, and no grade 3/4 complications occurred. All grade 1 and 2 complications were transient and resolved completely. There was no significant change in mean IPSS from baseline (-1, p = 0.460) and QoL (0, p = 0.441) scores following FLA but there was a significant drop in mean SHIM scores (-2, p = 0.010) compared to pretreatment baselines. Mean PSA significantly decreased after FLA (-2.5, p < 0.001). Seven out of 15 patients (46.67%) had residual cancer in, adjacent, or in close proximity to the treatment area (1 × 4+3=7, 1 × 3+4=7, and 5 × 3+3=6). Four out of 15 patients (26.67%) underwent salvage therapy (2 repeat FLA, 2 radical prostatectomy). CONCLUSION: After 3 years of follow-up we conclude focal laser ablation is safe and feasible without significant complications.
Identifier to cite or link to this itemhttp://hdl.handle.net/10713/15878
- MR imaging-guided focal laser ablation for prostate cancer: phase I trial.
- Authors: Oto A, Sethi I, Karczmar G, McNichols R, Ivancevic MK, Stadler WM, Watson S, Eggener S
- Issue date: 2013 Jun
- Focal Therapy for Prostate Cancer with In-Bore MR-guided Focused Ultrasound: Two-Year Follow-up of a Phase I Trial-Complications and Functional Outcomes.
- Authors: Tay KJ, Cheng CWS, Lau WKO, Khoo J, Thng CH, Kwek JW
- Issue date: 2017 Nov
- Phase II Evaluation of Magnetic Resonance Imaging Guided Focal Laser Ablation of Prostate Cancer.
- Authors: Eggener SE, Yousuf A, Watson S, Wang S, Oto A
- Issue date: 2016 Dec
- Complications, Recovery, and Early Functional Outcomes and Oncologic Control Following In-bore Focal Laser Ablation of Prostate Cancer.
- Authors: Lepor H, Llukani E, Sperling D, Fütterer JJ
- Issue date: 2015 Dec
- Magnetic resonance image-guided focal laser ablation in clinically localized prostate cancer: safety and efficacy.
- Authors: Al-Hakeem Y, Raz O, Gacs Z, Maclean F, Varol C
- Issue date: 2019 Dec